Applications are now closed!

Retina Innovation Lab

A collaborative program designed for medical teams dedicated to transforming retinal care and driving long-term patient adherence

In collaboration with The Israeli Ophthalmology Society

Israeli Ophthalmological Society

We invite you to bridge your clinical expertise with disruptive thinking in the Retina Innovation Lab to redefine the patient journey and drive better healthcare outcomes through patient-centered innovation.

We provide the tools and collaborative environment; you provide the clinical insight to address the most pressing challenges in long-term patient adherence and persistence.

What to Expect from the Lab

Patient-Centric Innovation Roadmap

Participate in a professional innovation program designed to offer a structured framework you to deeply map the patient journey and address real-world challenges to patient adherence and persistence

Expert Mentorship and Tools

We provide the professional facilitation and specialized tools necessary to navigate the program successfully, ensuring your medical center can translate complex challenges into actionable solutions

National Collaboration

Participation in two national innovation events

Professional Facilitation

Expert guidance through two on-site roundtables

Expert Consultation

Direct access to innovation specialists to refine your center’s strategy throughout the journey

Unique Patient Perspective

Exclusive exposure to the results of a comprehensive patient survey, providing a unique patient perspective

National Exposure and Networking

Exchange your center’s innovative ideas with the Lab’s Advisory Committee and engage in a high-level peer dialogue with retina departments across Israel

Implementation

The winning proposal shall be eligible to receive a gross amount of up to NIS 100,000 (VAT inclusive), to be used solely to advance the development of the proposal, subject to signing a separate collaboration agreement between the winner and Roche as stipulated in the program’s Official Rules

The Challenge: Bridging the Gap in Retinal Care

The Retina Innovation Lab invites you to identify the core gaps in adherence and persistence within your medical center and to draft practical, scalable solutions - whether clinical, operational, or digital - that will transform the patient journey and ensure that long-term treatment leads to better health outcomes.

Examples of pathways Retina Innovation Lab participants might explore:

Monitoring Optimization

Patient Support & Empowerment

Note: Proposals should not include additional manpower/personnel resources.

Applications are now closed!

Program Timeline

June 30, 2026
Call for Participation Opens: Medical teams are invited to submit their application to begin their journey of redefining retinal care.
July 31, 2026
Application Deadline
September 10, 2026 · 17:00-21:00
National Kick-off Event: Participating teams gather for an intensive launch session, featuring innovation workshops and expert-led training. Location: Beit Nizan, Romema 38 Tel-Aviv.
October-December, 2026
Phase 1: Patient Journey Mapping: Professionally facilitated “Roundtable I” sessions at each medical center to identify critical gaps in the patient journey.
January-March, 2027
Phase 2: Solution Design: “Roundtable II” sessions where teams architect clinical, operational, or digital solutions to the gaps identified.
April 8, 2027
Submission of Final Solution Proposals: The deadline for teams to submit their completed proposal for Advisory Committee review.
May 20, 2027 · 17:00-20:00
Final Showcase Event: The culmination of the innovation journey, where teams pitch their solutions to the Advisory Committee.

Advisory Committee

Our Team

Anat Arbel Shamir

Anat Arbel Shamir

Program Lead
Innovation & Policy Lead
Roche Pharma Israel
Tehila Levy-Talmi

Tehila Levy-Talmi

Ophthalmology Therapeutic Area Lead
Roche Pharma Israel
Nadia Lander

Nadia Lander

Ophthalmology Patient Journey Partner
Roche Pharma Israel
Orly Margolin Chen

Orly Margolin Chen

Ophthalmology Patient Journey Partner
Roche Pharma Israel
Shani Potesman Yona

Shani Potesman Yona

Ophthalmology Medical Manager
Roche Pharma Israel
Maytal Rabinovitch

Maytal Rabinovitch

Ophthalmology Patient Journey Partner
Roche Pharma Israel
Hadar Zalmanovich

Hadar Zalmanovich

Ophthalmology Patient Journey Partner
Roche Pharma Israel
Moran Nakar

Moran Nakar

Ophthalmology Patient Journey Partner
Roche Pharma Israel
Ravit Eyal

Ravit Eyal

Health System Partner, Real World Data Lead
Roche Pharma Israel
Haim Finkelstein

Haim Finkelstein

Health System Partner Lead
Roche Pharma Israel

Frequently Asked Questions

General Information

The Retina Innovation Lab, as part of the Roche for a Better Future Innovation Program, is designed for medical teams dedicated to transforming retinal care and driving long- term improvements in patient adherence and persistence.

 

The program is open to medical centers that can assemble a multidisciplinary team, including a retina specialist, retina resident and innovation expert. Additional team members may include a nurse, administration representative, and patient experience representative, and/or any additional participants as the Medical Center deems appropriate. Up to 5 medical centers will be selected to participate in the program.

 

Participation in the program is provided at no cost for the selected medical centers. Roche provides the professional framework, external moderation, and tools throughout the program roadmap.

The Process

Participating centers are expected to form a dedicated team and participate in a national launch event, two “Round Table” workshops within the medical center, and a final national showcase.

Teams will be asked to provide a summary report of the patient journey after the first workshop and a detailed proposal for their solution, including a budget outline, if needed, following the second workshop.

Independently of the Lab, Roche will conduct a patient survey to identify challenges to adherence from the patient’s perspective. The results will be shared with the Lab participants.

The Selection Process

The Advisory Committee will evaluate the proposals and provide recommendations based on their scalability (addressing a broad challenge), feasibility to implement, and their impact on long term patient adherence. The final selection is made by Roche.

For the avoidance of doubt, Roche will not be able to provide or support any manpower/personnel resources. 

No. This program is not focused on any specific medication, and there should be no product promotion within the solution.

Winning Proposal/s shall be eligible to receive a gross amount of up to NIS 100,000 (VAT inclusive) to be used solely to advance the development of the Proposal (“Monetary Grant”). The Monetary Grant shall be subject to signing a separate collaboration agreement between the winner and Roche. For the avoidance of doubt, if such collaboration agreement is not executed for any reason, no Monetary Grant will be awarded or paid. For the avoidance of doubt, Roche will not be able to provide or support any manpower/personnel resources. It is clarified that Roche may, in its sole discretion, select more than one (1) winner under the Program and, in such case, Roche may allocate and split the Monetary Grant among two (2) or more winners in such amounts and on such terms as Roche may determine in its sole discretion.